SGN-15

SGN-15

A formulation of a monoclonal antibody bound to a cytotoxic antibiotic (BR96-doxorubicin) which made it to Phase-II trials with “encouraging trends” reported for managing lung cancer. Its sponsorship ceased in 2005.
References in periodicals archive ?
The number of clinical trials was expanded with the initiation of the SGN-15 study in lung cancer.
SGN-15 is presently being tested in phase II trials for the treatment of breast, colon, lung and prostate cancers.
The trial will evaluate SGN-15 in combination with the chemotherapeutic drug Taxotere(R).
Reported data on phase II clinical trials of SGN-15 at the 11th World Conference on Lung Cancer.
Nasdaq:SGEN) today reported data from its phase II clinical trials of SGN-15 at the 11th World Conference on Lung Cancer being held in Barcelona, Spain.
The phase II studies presented at the World Conference on Lung Cancer were designed to assess the optimal dosing schedule of SGN-15 in combination with Taxotere, a chemotherapy treatment, in patients with non-small cell lung cancer (NSCLC).
Our clinical data confirm what we observed in our preclinical studies, which indicated that dosing SGN-15 prior to Taxotere enhances the therapeutic effect of the combination as compared to concurrent administration," said Clay B.
SGN-15 is a first-generation antibody-drug conjugate (ADC) that utilizes a hydrazone linker to target the cell-killing drug doxorubicin to tumor tissues expressing a Lewis-Y-related antigen.
The company has built a diverse portfolio of product candidates targeted to many types of cancer, including three being tested in multiple ongoing clinical trials, SGN-30, SGN-15 and SGN-40, and four in preclinical development, SGN-35, SGN-70, SGN-75 and SGN-17/19.
This increase was primarily driven by expanded clinical trial activity for the company's SGN-30, SGN-40 and SGN-15 product candidates, as well as growth of the company's workforce and related laboratory expenses.
This increase was primarily driven by higher levels of contract manufacturing of clinical grade materials and expanded clinical trial activity for the company's SGN-30, SGN-40 and SGN-15 product candidates.
Siegall will present an overview of the company focusing on its three clinical product candidates, SGN-30, SGN-15 and SGN-40, its preclinical programs and its industry-leading antibody-drug conjugate (ADC) technology.